TGF-beta Mimicking Peptide Stability and Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The utilization of transforming growth factor-beta (TGF-β) is limited due to poor expression, high production cost, and short half-life, which restricts its widespread application and effectiveness in treating related disorders or conditions.
Innovation Solution
Development of human TGF-β-derived peptides with enhanced characteristics such as activity, skin penetration, and stability, incorporating a cell adhesion amino acid sequence and protection groups like acetyl or PEG, which are linked to the N-terminal or C-terminal of the peptide, improving its stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural TGF-β is used, then biological activity is achieved, but production cost is high and half-life is short
Solution Approach 1:
The patent divides the TGF-β protein into a smaller peptide fragment (amino acid sequence Cys-Leu-Asp-Thr-Gln-Asp-Tyr-Ile-Trp-Ser-Leu-Asp-Thr-Gln-Asp-Tyr) that retains the essential biological activity. This segmentation reduces molecular size from the full TGF-β protein to a 20-amino acid peptide, improving stability and half-life while maintaining functional efficacy in preventing melanin production and promoting collagen synthesis.
Solution Approach 2:
The patent creates a simplified copy of the TGF-β molecule by identifying and isolating the critical active region (amino acid residues 65-84). This copy contains only the essential functional elements needed for biological activity, eliminating unnecessary portions of the protein structure that contribute to its short half-life and high production cost while preserving the core biological functions.
2Reliability
If TGF-β is used, then biological activity is achieved, but production cost is high
Solution Approach 1:
By segmenting TGF-β into a 20-amino acid peptide, the patent dramatically simplifies the manufacturing process. The smaller peptide can be produced through more efficient synthetic methods compared to producing the full TGF-β protein, reducing production costs while maintaining the essential biological activities of melanin inhibition and collagen promotion.
Solution Approach 2:
The patent creates a minimal functional copy of TGF-β that contains only the essential amino acid sequence (residues 65-84) required for biological activity. This copy can be synthesized more economically than the complete TGF-β protein, achieving cost reduction while preserving the core functions of preventing melanin production and stimulating collagen synthesis.
3Stability of the object's composition
If peptide is derived from TGF-β, then stability and activity are improved, but molecular structure is simplified
Solution Approach 1:
The patent segments TGF-β into a focused 20-amino acid peptide that is inherently more stable due to its reduced size and simplified structure. The segmented peptide resists degradation more effectively and maintains its biological activity longer, demonstrating that structural simplification through segmentation can enhance stability while preserving essential functions.
Data Source
AI summary
The present invention relates to a transforming growth factor-beta (TGF-β)-mimicking peptide containing a particular amino acid sequence and a composition for preventing or treating TGF-β-effective disorders or conditions using the same. The peptide of the present invention may be much higher stability than natural-occurring TGF-β and improve drawbacks caused by high molecular weight of natural-occurring TGF-β. The peptide of this invention can be advantageously applied to treatment or improvement of TGF-β-effective disorders or conditions and have excellent efficacies on skin whitening and wrinkle improvement.